JessicaH_TX said:The GIP arm is doing real work rather than padding the label.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The "tirzepatide is simply better" summary irritates me. It is better on mean weight loss, and the cardiovascular outcome evidence is far thinner than semaglutide's. If the reason for treating is cardiovascular risk rather than weight, the evidence base points the other way.
If somebody has the primary source to hand I would rather cite it than paraphrase it.
One concrete data point for the thread. Say what you would expect to see if you were wrong, before you look. It is a small discipline and it changes what you notice.
Dr.LipidDallas said:The "tirzepatide is simply better" summary irritates me.
There is a second half to this that has not been said yet. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.
Correct me if the detail matters more than I have assumed.
Sigma-Aldrich — Research-Grade Standards
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsFollowing on from MounjBrad — and this may be the naive question:
Whether anyone has held 10mg long term rather than climbing, and what happened over the following year?
Reporting back.
Update: the eight-week restart pattern people described is exactly what happened. I nearly abandoned it at week five.